

# Systemic Autoimmune Diseases in Patients with Hepatitis C Virus Infection: Characterization of 1020 Cases (The HISPAMEC Registry)

MANUEL RAMOS-CASALS, SANDRA MUÑOZ, FRANCISCO MEDINA, LUIS-JAVIER JARA, JOSÉ ROSAS, JAIME CALVO-ALEN, PILAR BRITO-ZERÓN, XAVIER FORNS, and JOSE-MARIA SÁNCHEZ-TAPIAS, for the HISPAMEC Study Group

**ABSTRACT. Objective.** To describe the clinical and immunologic characteristics of a large series of patients with systemic autoimmune diseases (SAD) associated with chronic hepatitis C virus (HCV) infection.

**Methods.** The HISPAMEC Registry is a multicenter international study group dedicated to collecting data on patients diagnosed with SAD with serological evidence of chronic HCV infection. The information sources are cases reported by physicians of the HISPAMEC Study Group and periodic surveillance of reported cases by a Medline search updated up to December 31, 2007.

**Results.** One thousand twenty HCV patients with SAD were included in the registry. Patients were reported from Southern Europe (60%), North America (15%), Asia (14%), Northern Europe (9%), South America (1%), and Australia (1%). Countries reporting the most cases were Spain (236 cases), France (222 cases), Italy (144 cases), USA (120 cases), and Japan (95 cases). The most frequently reported SAD were Sjögren's syndrome (SS; 483 cases), rheumatoid arthritis (RA; 150 cases), systemic lupus erythematosus (SLE; 129 cases), polyarteritis nodosa (78 cases), antiphospholipid syndrome (59 cases), inflammatory myopathies (39 cases), and sarcoidosis (28 cases). Twenty patients had 2 or more SAD. Epidemiological data were available in 677 cases. Four hundred eighty-seven (72%) patients were female and 186 (28%) male, with a mean age of  $49.5 \pm 1.0$  years at SAD diagnosis and  $50.5 \pm 1.1$  years at diagnosis of HCV infection. The main immunologic features were anti-nuclear antibody (ANA) in 61% of patients, rheumatoid factor (RF) in 57%, hypocomplementemia in 52%, and cryoglobulins in 52%. The main differential aspect between primary and HCV-related SAD was the predominance of cryoglobulinemic-related markers (cryoglobulins, RF, hypocomplementemia) over specific SAD-related markers (anti-ENA antibodies, anti-dsDNA, anti-cyclic citrullinated peptide) in patients with HCV.

**Conclusion.** In the selected cohort, the SAD most commonly reported in association with chronic HCV infection were SS (nearly half the cases), RA and SLE. Nearly two thirds of SAD-HCV cases were reported from the Mediterranean area. In these patients, ANA, RF and cryoglobulins are the predominant immunological features. (J Rheumatol First Release April 15 2009; doi:10.3899/jrheum.080874)

## Key Indexing Terms:

HEPATITIS C VIRUS    SJÖGREN'S SYNDROME    SYSTEMIC LUPUS ERYTHEMATOSUS  
RHEUMATOID ARTHRITIS    POLYARTERITIS NODOSA  
ANTIPHOSPHOLIPID SYNDROME    LYMPHOMA

The hepatitis C virus (HCV) is a linear, single-stranded RNA virus of the *Flaviviridae* family that was identified in 1989 and is recognized as the major causal agent of non-A,

non-B hepatitis<sup>1</sup>. The global prevalence of HCV infection has been estimated at nearly 3%, with a substantial geographic variation<sup>2</sup>. The lowest prevalence rates for HCV

From the Laboratory of Autoimmune Diseases "Josep Font," Department of Autoimmune Diseases, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Spain; Department of Rheumatology, Hospital de Especialidades, Centro Médico Nacional Siglo XXI and Centro Médico Nacional La Raza, Mexico DF, Mexico; Rheumatology Unit, Hospital de la Vila-Joiosa, Vila-Joiosa, Alacant; Rheumatology Unit, Hospital de Sierrallana, Santander; and Liver Unit, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Spain.

Supported by Grant FIS 04/0701.

M. Ramos-Casals, MD, PhD; S. Muñoz, MD, Laboratory of Autoimmune Diseases "Josep Font," Department of Autoimmune Diseases, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); F. Medina,

MD, Department of Rheumatology, Hospital de Especialidades, Centro Médico Nacional Siglo XXI; L.-J. Jara, MD, Centro Médico Nacional La Raza; J. Rosas, MD, PhD, Rheumatology Unit, Hospital de la Vila-Joiosa; J. Calvo-Alen, MD, PhD, Rheumatology Unit, Hospital de Sierrallana; P. Brito-Zerón, MD, PhD, Laboratory of Autoimmune Diseases "Josep Font," Department of Autoimmune Diseases, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); X. Fornas, MD, PhD; J.-M. Sánchez-Tapias, MD, PhD, Liver Unit, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS).

Address reprint requests to Dr. M. Ramos-Casals, Servei de Malalties Autoimmunes, Hospital Clínic, C/Villarroel, 170, 08036-Barcelona, Spain. E-mail: mramos@clinic.ub.es

Accepted for publication January 16, 2009.

infection in blood donors has been reported in Northern Europe (< 0.01%), followed by the USA and Western Europe (0.2%–0.5%) and South America, Eastern Europe and the Mediterranean area (1%–5%), with Egypt having the highest prevalence rate (> 15%)<sup>3</sup>. However, these prevalence rates determined from blood donors probably underestimate HCV prevalence in the general population<sup>3</sup>, and a US national survey found a prevalence 4-fold higher in the general population than in volunteer blood donors (1.8% vs 0.4%, respectively)<sup>4,5</sup>.

A decade ago, various investigators described the association of HCV infection with a heterogeneous group of “non-hepatic” conditions, such as pulmonary fibrosis, cutaneous vasculitis, glomerulonephritis, Mooren ulcers, and porphyria cutanea tarda or lichen planus<sup>6</sup>, which have since been considered “extrahepatic” manifestations of HCV infection, although it is currently accepted that a weak degree of association exists in some of them. Cryoglobulinemia was the first systemic autoimmune disease (SAD) clearly associated with HCV, and several groups reported that > 80% of patients with cryoglobulinemia had HCV infection<sup>7,8</sup>. The association between HCV and other SAD is less clear, and there is growing interest in the possible relationships, especially with Sjögren’s syndrome (SS), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), systemic vasculitis, and sarcoidosis<sup>9,10</sup>. However, a differing degree of association has been described for each SAD, possibly related to the variations in the overlap between extrahepatic HCV features and those included in the current classification criteria of the different SAD.

The aims of our study were to describe the clinical and immunological expression of HCV patients with SAD and to analyze the percentage of each individual criterion fulfilled by these patients for each SAD.

## MATERIALS AND METHODS

**Patients.** The Hispanoamerican Study Group of Autoimmune Manifestations associated with Hepatitis C Virus (HISPAMEC) is a multicenter study group consisting of various reference centers with substantial experience in the management of SAD and chronic HCV infection. A protocol form was designed to record the clinical and serologic characteristics of patients diagnosed with SAD who had serological evidence of chronic HCV infection (at least 2 positive determinations by a third-generation ELISA and/or positive HCV-RNA by polymerase chain reaction), with the aim of creating a registry of patients with SAD associated with chronic HCV infection. HCV patients with “primary” cryoglobulinemia (not associated with other SAD) are excluded. The information sources are cases reported by physicians of the HISPAMEC Study Group and periodic surveillance of reported cases by a Medline search updated up to December 31, 2007. The criteria for including cases identified in the literature search were the same as those applied to patients reported by HISPAMEC physicians (serological evidence of chronic HCV infection and fulfillment of the current classification criteria of the corresponding SAD). Only cases in which sufficient reliable information was available were included.

To minimize possible interobserver bias, the inclusion criteria and variables of the protocol were agreed on by all the participating physicians. Information collected by protocol forms was transferred to a computerized database program (SPSS for Windows; SPSS, Chicago, IL, USA). The pro-

col included written consent from patients and conformed to the ethical standards currently applied in the different centers involved.

**Definition of clinical features.** Salient features included in the protocol form were: (1) sex; (2) age at diagnosis of SAD, defined as the age when the patient fulfilled the current criteria for the classification of the respective SAD; (3) age at diagnosis of chronic HCV infection, defined as the first serological evidence of positive HCV antibodies; (4) classification criteria fulfilled for the respective SAD; (5) cumulative hepatic and extrahepatic manifestations; and (6) laboratory findings. Due to the retrospective study design, the data are presented as patients having the feature/patients in whom the feature was studied.

The diagnosis of SAD was based on the following classification criteria: (1) SS according to the preliminary diagnostic criteria proposed in 1993 by the European Community Study Group<sup>11</sup>; (2) SLE according to the revised criteria of the American College of Rheumatism (ACR)<sup>12</sup>; (3) RA according to the ACR criteria<sup>13</sup>; (4) systemic sclerosis according to the ACR preliminary criteria<sup>14</sup>; (5) polymyositis-dermatomyositis according to the Bohan and Peter criteria<sup>15</sup>; (6) primary antiphospholipid syndrome (APS) according to the preliminary classification criteria<sup>16</sup>; and (7) systemic vasculitis according to the consensus nomenclature proposed by Jennette, *et al*<sup>17</sup>.

## RESULTS

**General characteristics.** One thousand twenty HCV patients with SAD were included in the registry (last update December 31, 2007). Patients were reported from Southern Europe (60%), North America (15%), Asia (14%), Northern Europe (9%), South America (1%), and Australia (1%). The countries reporting the most cases were Spain (236 cases), France (222 cases), Italy (144 cases), USA (120 cases), and Japan (95 cases; Table 1).

The most frequent reported SAD were SS (483 cases),

Table 1. Countries reporting 1020 cases of SAD-HCV included in the HISPAMEC Registry.

Country	Patients, n (%)
Spain	236 (23.27)
France	222 (21.76)
Italy	144 (14.11)
USA	120 (11.76)
Japan	95 (9.31)
Russia	44 (4.31)
Mexico	34 (3.33)
Germany	30 (2.94)
Israel	27 (2.64)
China	21 (2.05)
Hungary	13 (1.27)
Portugal	7 (0.68)
Turkey	6 (0.58)
Poland	6 (0.58)
Greece	3 (0.29)
Rumania	3 (0.29)
Sweden	2 (0.19)
Australia	2 (0.19)
Columbia	1 (0.09)
India	1 (0.09)
Holland	1 (0.09)
Switzerland	1 (0.09)
Belgium	1 (0.09)

RA (150 cases), SLE (129 cases), polyarteritis nodosa (PAN; 78 cases), APS (59 cases), inflammatory myopathies (39 cases), and sarcoidosis (28 cases; Table 2). In addition to the corresponding SAD, 10 patients had lichen planus and 2 porphyria cutanea tarda. Twenty patients had 2 or more SAD. Epidemiological data were available in 677 cases. Four hundred eighty-seven (72%) patients were female and 186 (28%) male, with a mean age of  $49.5 \pm 1.0$  years at SAD diagnosis and  $50.5 \pm 1.1$  years at diagnosis of HCV infection. The main immunologic features were antinuclear antibodies (ANA) in 61% of patients, rheumatoid factor (RF) in 57%, hypocomplementemia in 52%, and cryoglobulins in 52% (Table 3). There were 16 patients with HBV coinfection

(all with PAN) and 10 with HIV coinfection (6 with PAN, 2 with APS, and 2 with inflammatory myopathy).

Seventy-five SAD-HCV patients included in the registry developed neoplasia, most frequently hematological (42 cases, 35 of which were B cell lymphoma) and hepatocellular carcinoma (16 cases). Five patients developed 2 neoplasias.

**SS-HCV.** There were 483 patients with SS-HCV included in the registry (79% women, mean age  $53.6 \pm 1.5$  yrs at SS diagnosis and  $55.2 \pm 1.1$  yrs at diagnosis of HCV). Patients fulfilled the following SS criteria: xerophthalmia in 430/440 (97%) patients, xerostomia in 427/440 (97%), positive Schirmer test in 236/242 (98%), altered rose Bengal staining in 13/14 (93%), altered salivary flow in 21/26 (81%), positive salivary scintigraphy in 135/159 (85%), positive salivary gland biopsy in 191/259 (74%), ANA in 181/266 (68%), RF in 130/243 (53%), and anti-Ro/La in 69/269 (25%).

**SLE-HCV.** There were 129 patients with SLE-HCV (85% women, mean age  $39 \pm 3.4$  yrs at SLE diagnosis and  $40.1 \pm 2.6$  yrs at HCV diagnosis). Patients fulfilled the 1997 SLE criteria<sup>12</sup>: ANA in 123/125 (98%) patients, arthritis in 87/102 (85%), positive anti-dsDNA in 86/105 (82%), cytopenias in 70/120 (69%), malar rash in 65 (62%), positive antiphospholipid antibodies (aPL) in 54/115 (47%), nephropathy in 43/102 (43%), positive anti-Sm in 16/43 (37%), oral ulcers in 31/102 (30%), serositis in 29/102 (29%), photosensitivity in 26/102 (25%), neurologic involvement in 8/102 (8%), and discoid lupus in 2 (2%).

**RA-HCV.** There were 150 patients with RA-HCV (76% women, mean age  $53 \pm 3.2$  yrs at RA diagnosis and  $57 \pm 2.2$  yrs at HCV diagnosis). Features in the RA classification criteria were arthritis of more than 3 articular areas in 109/111 (98%), arthritis of hands 106/111 (95%), symmetric arthritis 106/111 (95%), positive RF 110/111 (99%), radiographic changes 98/111 (89%), morning stiffness 74/111 (67%), and rheumatoid nodules 8/111 (7%).

**PAN-HCV.** Seventy-eight patients were diagnosed with PAN (41% women, mean age  $44 \pm 3.6$  yrs at PAN diagnosis and

Table 2. Systemic autoimmune disease (SAD) in patients with HCV infection: cases included in the HISPAMEC Registry.

SAD	Patients, n (%)
Sjögren syndrome	483 (47.5)
Rheumatoid arthritis	150 (14.7)
Systemic lupus erythematosus	129 (12.6)
Polyarteritis nodosa	78 (7.6)
Antiphospholipid syndrome	59 (5.8)
Inflammatory myopathies	39 (3.8)
Sarcoidosis	28 (2.7)
Systemic sclerosis	11 (1.1)
Behçet disease	10 (< 1)
Temporal arteritis	7 (< 1)
ANCA-glomerulonephritis	5 (< 1)
Urticaria-vasculitis	4 (< 1)
Ankylosing spondylitis	3 (< 1)
Wegener granulomatosis	3 (< 1)
Churg-Strauss vasculitis	2 (< 1)
Henoch-Schönlein purpura	2 (< 1)
Central nervous system vasculitis	1 (< 1)
Relapsing polychondritis	1 (< 1)
Microscopic polyangiitis	1 (< 1)
Polymyalgia rheumatica	1 (< 1)
Mixed connective tissue disease	1 (< 1)
Takayasu arteritis	1 (< 1)
Goodpasture syndrome	1 (< 1)
Total	1020 (100)

Table 3. Immunological markers in patients with SAD-HCV.

SAD	Antinuclear Antibody, Positive/total (%)	Rheumatoid Factor, Positive/total (%)	Hypocomplementemia, Positive/total (%)	Cryoglobulinemia, Positive/total (%)
Sjögren syndrome	181/266 (68)	130/243 (53)	107/212 (50)	147/314 (47)
Rheumatoid arthritis	23/43 (53)	110/111 (99)	30/55 (55)	13/38 (34)
Systemic lupus erythematosus	123/125 (98)	14/44 (32)	77/110 (70)	50/87 (58)
Polyarteritis nodosa	2/8 (25)	21/40 (52)	19/45 (42)	24/48 (50)
Antiphospholipid syndrome	5/15 (33)	6/16 (38)	9/16 (56)	7/16 (44)
Inflammatory myopathies	9/17 (53)	1/13 (8)	2/15 (13)	3/18 (17)
Other systemic vasculitis	5/20 (25)	4/19 (21)	8/19 (42)	17/25 (68)
Systemic sclerosis	9/10 (90)	5/10 (50)	0/10 (0)	2/10 (20)
Sarcoidosis	2/8 (25)	1/8 (13)	0/8 (0)	1/9 (11)
Other diseases	2/4 (50)	2/4 (50)	0/3 (0)	2/3 (67)

42 ± 3.7 yrs at HCV diagnosis). Patients fulfilled the classification criteria of PAN: necrotizing inflammation of medium or small arteries in biopsy specimens in 54/57 (95%) patients, livedo reticularis 35/57 (61%), weight loss 34/57 (60%), polyneuropathy 34/57 (60%), myalgias or weakness 33/57 (58%), altered arteriography 28/57 (49%), hypertension 21/57 (37%), raised creatinine 15/57 (26%) and positive HBsAg in 15/57 (26%). No patient presented with testicular involvement.

**APS-HCV.** There were 59 patients with APS-HCV (46% women, mean age 47 ± 2.6 yrs at APS diagnosis and 49 ± 2.5 yrs at diagnosis of HCV). Patients fulfilled the following criteria for APS: positive aPL in 59 (100%) patients, thrombosis in 51 (87%), and fetal losses in 9 (14%).

**Inflammatory myopathies-HCV.** There were 39 HCV patients with inflammatory myopathies (59% women, mean age 52 ± 2.1 yrs at diagnosis of inflammatory myopathies and 49 ± 2.5 yrs at diagnosis of HCV). Patients fulfilled the following classification criteria for inflammatory myopathies: myopathic changes on electromyography 34/34 (100%), proximal muscle weakness 33/34 (97%), increased serum concentrations of muscle enzymes 33/34 (97%), histopathological findings consistent with inflammatory myositis in 33/34 (97%), and skin lesions suggestive of dermatomyositis in 13/34 (38%).

**Sarcoidosis-HCV.** There were 28 HCV patients with sarcoidosis unrelated to antiviral therapy (70% women, mean age 50 ± 4.76 yrs at diagnosis of sarcoidosis and 54 ± 3.75 yrs at diagnosis of HCV). Twenty out of 24 (83%) patients presented respiratory symptoms, 10/24 (42%) cutaneous involvement, extrapulmonary adenopathies in 12/24 (50%; cervical in 8, supraclavicular in 3, inguinal in 2, abdominal in 1), articular involvement in 3/24 (13%) patients, renal involvement in 1/24 (4%), and parotid gland involvement in 2/24 (7%).

**Other SAD-HCV.** The remaining 54 patients, with SAD-HCV, presented different diseases, of which systemic sclerosis (n = 11), Behçet disease (n = 10), Horton disease (n = 7), and anti-neutrophil cytoplasmic antibody (ANCA)-glomerulonephritis (n = 5) were the most frequent (Table 2).

## DISCUSSION

Viruses are often proposed as etiologic or triggering agents of SAD. HCV is the chronic viral infection most frequently related to the development of autoimmune processes, both clinical and immunological. The specific tropism of HCV for many extrahepatic cell types, as reported<sup>8</sup>, provides the basis for a link between HCV and the development of extrahepatic manifestations.

Although nearly 40% of unselected patients with HCV have at least one clinical or analytical extrahepatic feature<sup>18</sup>, the prevalence of patients fulfilling SAD criteria is much lower (2%–6%). For this reason, the HISPAMEC Registry

has compiled data for 1020 HCV patients with coexisting SAD, which has allowed characterization of the clinical expression of SAD in patients with chronic HCV infection. The most frequent SAD included in the HISPAMEC Registry, representing 90% of cases, are SS, SLE, RA, and PAN. Other SAD, such as systemic sclerosis, inflammatory myopathies, sarcoidosis and ANCA-related vasculitis, are uncommon. These data, together with those from series of SAD patients tested for HCV infection<sup>19</sup>, confirm the predominant association of HCV with specific SAD.

The majority of studies reporting analysis of the prevalence of chronic HCV infection in patients with SAD found a higher prevalence than that in the general population. However, these prevalences vary widely according to geographic area<sup>20</sup>. The best example is SS: studies from southern Europe describe a prevalence of HCV infection in SS patients between 10% and 20%, while studies from Scandinavia and the US<sup>21,22</sup> found a prevalence < 1%, probably due to the lower prevalence of HCV infection in these countries<sup>23</sup>. Seventy percent of all reported cases of SAD in patients with HCV infection come from 3 Mediterranean countries (Spain, France, and Italy), underlining this geographic variability.

Currently, SS should be considered the SAD most closely associated with HCV, first because recent experimental evidence in mice<sup>24</sup> and humans<sup>25</sup> supports the sialotropism of HCV<sup>26</sup>, and second, because clinical evidence shows that SS is the SAD with the highest prevalence of chronic HCV infection, which was detected in 151 (18%) of the 858 SS patients tested<sup>27</sup>. In the HISPAMEC Registry, SS accounts for 47% of the SAD associated with HCV. Analysis of these cases has identified a considerable overlap between SS classification criteria and extrahepatic features of HCV infection, especially with respect to sicca syndrome (both subjective and objective), histopathological criteria, and immunological markers such as ANA and RF. This shows that a clinical diagnosis of SS could easily be made in patients with HCV presenting with sicca syndrome and positive ANA and/or RF. In contrast, positive anti-Ro/La antibodies were described in only 25% of patients with SS-HCV, a prevalence that is half that found in primary SS<sup>28</sup>. This suggests that the main differential aspect between primary and HCV-related SS is the immunological pattern, with a predominance of cryoglobulin-related markers (mixed cryoglobulins, RF, hypocomplementemia) over SS-related markers (anti-Ro/SSA and anti-La/SSB autoantibodies)<sup>29</sup>. In addition, we recently found a 3-fold higher prevalence of hypocomplementemia in patients with SS-HCV compared with patients with primary SS<sup>30</sup>. Other studies have found a close association between SS and HCV. Sicca syndrome was the second most frequent extraglandular manifestation in the largest series of unselected HCV patients reported<sup>31</sup>, with a prevalence of 11%. In another study, SS was diagnosed in 5% of 147 unselected HCV patients, a prevalence 5-fold

greater than that of the general population<sup>32</sup>. Finally, Caporali, *et al*<sup>33</sup> recently found that 15% of 501 patients in whom salivary gland biopsy was carried out due to a clinical suspicion of SS were HCV-positive.

With respect to SLE, chronic HCV infection can induce clinical and serologic features that together can meet the ACR 1997 revised criteria for SLE<sup>12</sup>. First, some clinical criteria such as arthritis and glomerulonephritis may be observed in HCV patients, especially in the context of associated cryoglobulinemia. Second, cytopenias such as thrombocytopenia and leukopenia are also frequently found in patients with HCV. Third, unselected HCV patients have a higher prevalence of some immunological markers included in the SLE criteria, such as ANA and aPL (nearly 20%<sup>18</sup>), and even low to moderate titers of anti-dsDNA antibodies<sup>34</sup>. In contrast, other SLE criteria have been described rarely in HCV patients with extrahepatic involvement (SLE-related cutaneous features, oral ulcers, central nervous system involvement, hemolytic anemia, anti-Sm antibodies, and high titers of anti-dsDNA)<sup>35</sup>. However, since some patients with SLE-HCV do present these features, we suggest that this subset of patients should be considered as having true coexistence of SLE and chronic HCV infection. Although the pathogenic role of HCV infection in these patients is unclear, it is possible that HCV acts as a triggering factor in some patients with a specific genetic background.

It is understandable that HCV patients presenting with polyarthritis and positive RF could be clinically classified as having RA. Of the current ACR classification criteria, there are 4 (arthritis of  $\geq 3$  joint areas, arthritis of hand joints, symmetric arthritis, and serum RF) that are usually found in patients with HCV infection. In 3 series that analyzed 75 HCV patients with arthritis<sup>36-38</sup>, nearly half fulfilled the ACR criteria for RA. Cryoglobulinemia (which causes arthritis and is associated with positive RF) plays a significant role in the overlap between extrahepatic HCV features and RA criteria, making the differentiation between cryoglobulinemic arthritis and HCV-related RA difficult. Erosive arthritis in HCV patients should be considered as highly specific for a true coexistence between HCV and RA, since cryoglobulinemic arthritis is overwhelmingly nonerosive<sup>37,38</sup>. In addition, recent studies have focused on the potential role of antibodies to cyclic citrullinated peptides (CCP) in differentiating between RA and cryoglobulinemic-related arthritis in patients with chronic HCV infection. Wener, *et al*<sup>39</sup> found no anti-CCP antibodies in HCV patients, although some false-positive results were observed in patients with cryoglobulinemia, while Bombardieri, *et al*<sup>40</sup> found anti-CCP antibodies in 76% of patients with RA and in 60% of those with RA and HCV, but found none in HCV patients without RA. Sène, *et al*<sup>32</sup> investigated the diagnostic reliability of anti-CCP antibodies in distinguishing HCV-associated rheumatologic manifestations from RA and found that anti-CCP antibodies were the most specific

biological marker for RA, with a specificity of 93% and a positive predictive value of 96%. These studies strongly suggest that anti-CCP antibodies may discriminate HCV patients with true RA from those with HCV-associated arthritis.

Cryoglobulinemic-HCV patients may present several features such as weight loss, myalgia or weakness, peripheral neuropathy, elevated blood urea nitrogen/creatinine, and positive HBV markers that are included in the 1990 classification criteria for PAN. However, histopathological analysis can easily differentiate PAN from cryoglobulinemia, the 2 types of systemic vasculitis most frequently associated with HCV infection. PAN shows necrotizing inflammation of medium-size arteries in contrast to the leukocytoclastic vasculitis found in cryoglobulinemia. The remaining reported cases of systemic vasculitis in patients with HCV infection included isolated reports of giant cell arteritis, ANCA-related vasculitides, and Henoch-Schönlein purpura, but they were few in number, in contrast to about 80 reported cases of PAN-HCV. The 1990 criteria for these systemic vasculitides show a slight overlap with the most common extrahepatic HCV features, and their coexistence with HCV infection may be considered a chance phenomenon. Anecdotally, there are 2 reported cases of cryoglobulinemic vasculitis mimicking giant cell arteritis<sup>41,42</sup>, although careful analysis of histologic data led to correct diagnosis in both cases.

Cryoglobulinemia is the key immunological marker of SAD associated with HCV. Clinically, cryoglobulinemic-related features such as general malaise, fever, myalgia, vasculitis, arthritis, neuropathy, and glomerulonephritis may easily lead to fulfillment of classification criteria for some SAD (especially SLE, RA, and PAN) in HCV patients. In addition, the immunological profile of patients with HCV-related SAD is characterized by a clear predominance of cryoglobulinemic-related markers (cryoglobulins, RF, hypocomplementemia) over specific SAD-related markers (anti-extractable nuclear antigen, anti-dsDNA, anti-CCP). A very careful application of the current classification criteria for SAD in patients with chronic HCV infection is strongly recommended. However, current criteria for SAD were in fact validated without control groups of patients with chronic viral infections, making it impossible to ascertain whether these criteria may be useful in distinguishing the mimicking of a SAD by extrahepatic HCV manifestations, the coexistence of the 2 processes based on a common etiopathogenic basis, or a casual association of 2 prevalent processes. Indeed, there are criteria from some diseases (i.e., PAN) that include a chronic viral infection, while in others (such as SS) chronic viral infections are excluded. Future revisions of classification criteria may ideally include as controls not only healthy controls, but also patients with prevalent nonautoimmune diseases such as neoplasia or chronic viral infections.

Few studies have systematically investigated SAD in

unselected populations of patients with HCV. Only 2 studies<sup>18,43</sup> performed a complete evaluation of SAD in a total of 411 unselected HCV patients, finding that SS (n = 10), PAN (n = 9), and SLE (n = 6) were the 3 most frequently identified SAD. Two additional studies<sup>32,44</sup> specifically investigated SS in a total of 216 unselected HCV patients, and found that 11 (5%) fulfilled classification criteria for SS, a prevalence 5 to 10-fold greater than that described in the general population. These data show results similar to those from our registry.

Unlike epidemiological studies, our results offer a different viewpoint on the association between HCV and SAD, utilizing a registry of consecutive HCV patients who fulfilled classification criteria for SAD, a methodological approach that did not allow us to establish whether the degree of association between HCV and the different SAD was strong or weak. This explains why the prevalence of SS in large series of patients with HCV<sup>31,32,45</sup> ranges between 5% and 10% while in our registry SS represents 47%. In addition, there was a selection bias in some SAD. Thus, the high frequency of SS may be related to patient selection bias in the centers participating in the HISPAMEC and SS-HCV study groups (from Spain, Italy, France, and Mexico), most of whom are referral centers for SS. Of the 483 cases of SS included in the registry, 145 (30%) came from the study groups. A similar bias related to a specific interest in a specific SAD may also be observed in groups working in vasculitis<sup>18,31</sup> and RA<sup>36-39</sup>. Due to the study design, our results do not allow the assumption that patients with SAD-HCV included in our registry are representative of the frequency of the different SAD in the general HCV population, which makes it impossible to calculate the comparative prevalence of the SAD in patients with and without HCV infection.

We describe the main characteristics of a registry of 1020 patients with coexisting SAD and chronic HCV infection. Using these cumulative data, it cannot be determined whether there is an etiopathogenic association between HCV infection and SAD or whether the simultaneous diagnosis may be coincidental. However, it is notable that SS, SLE, RA, and PAN accounted for 80% of the total reported SAD-HCV cases. Given the significant overlap between extrahepatic HCV features and the current classification criteria for these SAD, we recommend that these criteria should be reevaluated to take the influence of HCV-related features into account.

## ACKNOWLEDGMENT

The authors thank David Buss for his editorial assistance.

*Members of the Hispanoamerican Study Group of Extrahepatic Manifestations of Hepatitis C Virus (HISPAMEC):* M. Ramos-Casals (Coordinator), P. Brito-Zerón, S. Muñoz, Laboratory of Autoimmune Diseases "Josep Font," Department of Autoimmune Diseases, Hospital Clinic, IDIBAPS, Barcelona, Spain; X. Forns, J.M. Sanchez-Tapias, Liver Unit, IDIBAPS, Hospital Clinic, Barcelona; A. López-Guillermo, Department of Hematology, Hospital Clinic, Barcelona; J. Rosas, G. Santos, Rheumatology Unit, Hospital de la Vila-Joiosa, Vila-Joiosa,

Alacant, Spain; F. Medina, Department of Rheumatology, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Mexico DF, Mexico; L.J. Jara, Department of Rheumatology, Hospital de Especialidades, Centro Médico Nacional La Raza, Mexico DF, Mexico; J.M. Anaya, Rheumatology Unit, Corporación para Investigaciones Biológicas and Clínica Universitaria Bolivariana, School of Medicine, Universidad Pontificia Bolivariana, Medellín, Colombia; J.C. Restrepo, Hospital Pablo Tobón Uribe and University of Antioquia, Medellín; J. Mañá, Department of Internal Medicine, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain.

## REFERENCES

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood borne non-A, non-B viral hepatitis genome. *Science* 1989;244:359-62.
2. Alter MJ, Mast EE. The epidemiology of viral hepatitis in the United States. *Gastroenterol Clin North Am* 1994;23:437-55.
3. Yen T, Keeffe EB, Ahmed A. The epidemiology of hepatitis C virus infection. *J Clin Gastroenterol* 2003;36:47-53.
4. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. *N Engl J Med* 1999;341:556-62.
5. Glynn SA, Kleinman SH, Schreiber GB, et al. Trends in incidence and prevalence of major transfusion-transmissible viral infections in US blood donors, 1991 to 1996. *Retrovirus Epidemiology Donor Study (REDS)*. *JAMA* 2000;284:229-35.
6. Gumber SC, Chopra S. Hepatitis C: a multifaceted disease. Review of extrahepatic manifestations. *Ann Intern Med* 1995;123:615-20.
7. Ferri C, Greco F, Longombardo G, et al. Antibodies to hepatitis C virus in patients with mixed cryoglobulinemia. *Arthritis Rheum* 1991;34:1606-10.
8. Marcellin P, Descamps V, Martinot-Peignoux M, et al. Cryoglobulinemia with vasculitis associated with hepatitis C virus infection. *Gastroenterology* 1993;104:272-7.
9. Haddad J, Deny P, Munz-Gotheil C, et al. Lymphocytic sialadenitis of Sjögren's syndrome associated with chronic hepatitis C virus liver disease. *Lancet* 1992;339:321-3.
10. Ramos-Casals M, Forns X, Sánchez-Tapias JM, Rodés J. Extrahepatic manifestations of HCV infection. In: Font J, Ramos-Casals M, Rodés J, editors. *Digestive involvement in systemic autoimmune diseases*. Amsterdam: Elsevier; 2008.
11. Vitali C, Bombardieri S, Moutsopoulos HM, et al. Preliminary criteria for the classification of Sjögren's syndrome. *Arthritis Rheum* 1993;36:340-7.
12. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. *Arthritis Rheum* 1997;40:1725.
13. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum* 1988;31:315-24.
14. Anonymous. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. *Arthritis Rheum* 1980;23:581-90.
15. Bohan A, Peter JB. Polymyositis and dermatomyositis. *N Engl J Med* 1975;292:344-47.
16. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. *Arthritis Rheum* 1999;42:1309-11.
17. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. *Arthritis Rheum* 1994;37:187-94.
18. Cacoub P, Renou C, Rosenthal E, et al. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective

- multicenter study of 321 patients. *Medicine (Baltimore)* 2000;79:47-56.
19. Ramos-Casals M, Font J, Ingelmo M. Prevalence and clinical significance of hepatitis C virus infection in systemic autoimmune diseases. *Med Clin (Barc)* 2001;116:701-9.
  20. Ramos-Casals M, Font J. Extrahepatic manifestations in patients with chronic hepatitis C virus infection. *Curr Opin Rheumatol* 2005;17:447-55.
  21. Verbaan H, Carlson J, Eriksson S, et al. Extrahepatic manifestations of chronic hepatitis C infection and the interrelationship between primary Sjogren's syndrome and hepatitis C in Swedish patients. *J Intern Med* 1999;245:127-32.
  22. King PD, McMurray RW, Becherer PR. Sjogren's syndrome without mixed cryoglobulinemia is not associated with hepatitis C virus infection. *Am J Gastroenterol* 1994;89:1047-50.
  23. Ramos-Casals M, Jara LJ, Medina F, et al; HISPAMEC Study Group. Systemic autoimmune diseases co-existing with chronic hepatitis C virus infection (the HISPAMEC Registry): Patterns of clinical and immunological expression in 180 cases. *J Intern Med* 2005;257:549-57.
  24. Koike K, Moriya K, Ishibashi K, et al. Sialadenitis histologically resembling Sjögren syndrome in mice transgenic for hepatitis C virus envelope genes. *Proc Natl Acad Sci USA* 1997;94:233-6.
  25. Arrieta JJ, Rodriguez-Inigo E, Ortiz-Movilla N, et al. In situ detection of hepatitis C virus RNA in salivary glands. *Am J Pathol* 2001;158:259-64.
  26. Ramos-Casals M, Garcia-Carrasco M, Cervera R, Font J. Is hepatitis C virus a sialotropic virus? *Am J Pathol* 2001;159:1593-4.
  27. Ramos-Casals M, Loustaud-Ratti V, Zeher M. Hepatitis C virus and autoimmune diseases. In: Ramos-Casals M, Garcia-Carrasco M, Rosas J, Calvo J, Font J, editors. *Enfermedades autoinmunes sistémicas y reumatológicas*. Barcelona: Ed. Masson; 2005:742-58.
  28. Ramos-Casals M, Solans R, Rosas J, et al. Primary Sjögren syndrome in Spain. Clinical and immunologic expression of 1010 patients (The GEMESS Cohort). *Medicine (Baltimore)* 2008;87:210-9.
  29. Ramos-Casals M, Loustaud-Ratti V, De Vita S, et al. Sjogren syndrome associated with hepatitis C virus: A multicenter analysis of 137 cases. *Medicine (Baltimore)* 2005;84:81-9.
  30. Ramos-Casals M, Brito-Zeron P, Yague J, et al. Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjogren's syndrome. *Rheumatology* 2005;44:89-94.
  31. Cacoub P, Poynard T, Ghillani P, et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. *Arthritis Rheum* 1999;42:2204-12.
  32. Sene D, Ghillani-Dalbin P, Limal N, et al. Anti-cyclic citrullinated peptide antibodies in hepatitis C virus associated rheumatological manifestations and Sjogren's syndrome. *Ann Rheum Dis* 2006;65:394-7.
  33. Caporali R, Bonacci E, Epis O, Bobbio-Pallavicini F, Morbini P, Montecucco C. Safety and usefulness of minor salivary gland biopsy: Retrospective analysis of 502 procedures performed at a single center. *Arthritis Rheum* 2008;59:714-20.
  34. Perlemuter G, Cacoub P, Sbai A, et al. Hepatitis C virus infection in systemic lupus erythematosus: a case-control study. *J Rheumatol* 2003;30:1473-8.
  35. Ramos-Casals M, Font J, Garcia-Carrasco M, et al. Hepatitis C virus infection mimicking systemic lupus erythematosus: Study of hepatitis C virus infection in a series of 134 Spanish patients with systemic lupus erythematosus. *Arthritis Rheum* 2000;43:2801-6.
  36. Lovy MR, Starkebaum G, Uberoi S. Hepatitis C infection presenting with rheumatic manifestations: a mimic of rheumatoid arthritis. *J Rheumatol* 1996;23:979-83.
  37. Rivera J, Garcia-Monforte A, Millan J. Extrahepatic symptoms as presenting manifestations of hepatitis C virus infection. *J Clin Rheumatol* 1999;5:268-72.
  38. Ueno Y, Kinoshita R, Tsujinoue H, Kato M. A case of hepatitis C virus (HCV)-associated arthritis. Quantitative analysis of HCV RNA of the synovial fluid and the serum. *Br J Rheumatol* 1995;34:691-2.
  39. Wener MH, Hutchinson K, Morishima C, Gretch DR. Absence of antibodies to cyclic citrullinated peptide in sera of patients with hepatitis C virus infection and cryoglobulinemia. *Arthritis Rheum* 2004;50:2305-8.
  40. Bombardieri M, Alessandri C, Labbadia G, et al. Role of anti-cyclic citrullinated peptide antibodies in discriminating patients with rheumatoid arthritis from patients with chronic hepatitis C infection-associated polyarticular involvement. *Arthritis Res Ther* 2004;6:R137-41.
  41. Genereau T, Martin A, Lortholary O, Noel V, Guillevin L. Temporal arteritis symptoms in a patient with hepatitis C virus associated type II cryoglobulinemia and small vessel vasculitis. *J Rheumatol* 1998;25:183-5.
  42. Lamprecht P, Gause A, Gross WL. Cryoglobulinemic vasculitis resistant to intermittent intravenous pulse cyclophosphamide therapy. *Scand J Rheumatol* 2000;29:201-2.
  43. Buskila D, Shnaider A, Neumann L, et al. Musculoskeletal manifestations and autoantibody profile in 90 hepatitis C virus infected Israeli patients. *Semin Arthritis Rheum* 1998;28:107-13.
  44. D'Amico E, Palazzi C, Cacciatore P, et al. Anti-ENA antibodies in patients with chronic hepatitis C virus infection. *Dig Dis Sci* 2002;47:755-9.
  45. Barrett S, Goh J, Coughlan B, et al. The natural course of hepatitis C virus infection after 22 years in a unique homogenous cohort: spontaneous viral clearance and chronic HCV infection. *Gut* 2001;49:423-30.